Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. QCOM
6. AZN
7. ORCL
8. AAPL
9. NVS
10. ROIV

Go back to Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary Endpoint
(NASDAQ: AVIR) Delayed: 5.68 --0 (-0%)
Previous Close $5.68    52 Week High $2.00 
Open $5.68    52 Week Low $1.15 
Day High $5.68    P/E N/A 
Day Low $5.68    EPS $0.00 
Volume 1,110